S&P 500 Positive for 'First Five Days,' Huang Sees Decades till Quantum | Wall Street Today

Kevin Travers16:12 ET

Palantir Stock Drops for 3rd Day. ARK Invest Unloads More Shares.

Barrons12:46 ET

Wednesday Market Falls, Quantum Computing Pulls Back Hard on Treasury Yield Crunch | Live Stock

Kevin Travers11:06 ET

Shake Shack, Morgan Stanley, Synovus Financial And A Communication Services Stock On CNBC's 'Final Trades'

BenzingaJan 8 08:52 ET

Today's Analyst Rating | UBS Upgrades Bank of America to Buy, Salesforce Price Target Raised to $400 by Needham

Moomoo NewsJan 8 08:00 ET · Ratings

Morgan Stanley: Maintains "Shareholding" rating for Giant Biotechnology with a Target Price of 65 Hong Kong dollars.

Morgan Stanley released a research report stating that it expects the stock price of Gigot Biotech (02367) to rise by about 70% to 80% over the next 15 days, setting its Target Price at HKD 65 and giving it a "Shareholding" rating. The bank forecasts the company's earnings growth for the fiscal years 2024 and 2025 to be 37% and 23%, respectively, indicating that the upcoming annual performance may be stronger than that of other companies within the bank's coverage. The report mentioned that Gigot Biotech's stock price has fallen by about 12% since mid-December last year, and the bank has not yet identified a fundamental reason but believes that the relevant performance is mainly influenced by market allocation. The bank also believes that if measured by 2025.

Sina Hong Kong StockJan 8 04:09 ET